The site on Microweg in Nijmegen is a campus under development, where more than 400 staff are working to fulfil patients’ hopes for a better quality of life. This is where Byondis is based, and the company is fully dedicated to developing precision medicines to treat intractable cancers and autoimmune diseases.Read more in this joint interview with Marco Timmers, CEO of Byondis and a member of The Economic Board, and John van Sambeek, civic entrepreneur for Health and High-tech at The Economic Board. What role can Byondis and other health and high-tech companies play in addressing the societal challenges we face?
Byondis' focus as a biopharmaceutical company
By developing effective and safe precision medicines,
Byondis aims to outsmart stubborn tumours and autoimmune diseases. The Nijmegen-based biopharmaceutical company has one goal: to fulfil patients’ hopes for new medicines to treat diseases for which there is currently no effective treatment. To this end, Byondis utilises innovative technologies that spare healthy cells as much as possible whilst targeting diseased cells. The lead programme focuses primarily on breast cancer, whilst the second programme targets lung cancer and other forms of cancer where this specific technology is likely to be most effective. It is important to be able to determine this in advance. Timmers: “More thorough stratification of patients prior to treatment can contribute to the development of successful new medicines. So, in which patients might the drug work and in which might it not? We are conducting intensive research into this, using biomarkers, amongst other things. In this way, you can save a huge amount of money and drastically improve the efficacy of the drugs in the right patient population. We will only develop a therapy if patients stand to benefit from it; otherwise, we won’t.”
Good healthcare staff
Van Sambeek: “The affordability of healthcare is one thing; securing good healthcare staff is another challenge we face. In our region, one in seven people works in the healthcare sector. By 2030, that ratio is expected to rise to one in four or five. We simply don’t have enough people to meet that demand, so we’ll need to tackle this by focusing more on prevention. But also by applying digital innovations that enable, for example, more remote care to be provided.
With the help of the recently drawn up Human Capital Agreement, the region is trying to address this staff shortage. Among other things, we are using this to raise the profile of the innovative companies in our region so that talented young people realise that they can also find work here in the region after completing their studies.”
Beyond this...
Byondis employs more than 400 people, whilst Synthon, also located on the Byondis campus, employs around 180. This means there are approximately 600 people working on the campus. The Dutch pharmaceutical company Synthon is Byondis’s former parent company and develops and manufactures high-quality generic medicines. It focuses on medicines whose patents have expired, with a view to producing them more efficiently and cost-effectively. Since 2012, Byondis has been taking this a step further by developing entirely new medicines, particularly to treat diseases where there is still much to be gained. Timmers: “We want to make a difference for patients. We need the right people to do that.”
The Economic Board: Triple Helix alliance
Van Sambeek: “We share a common interest in this, because what business do companies have here if there are no well-trained people, we cannot carry out clinical trials and there is no proper infrastructure? We need each other and want to establish more public-private partnerships. This requires a further intensification of knowledge exchange between research institutions, public authorities and businesses.
The Economic Board could be the driving force behind this, given that research institutions such as Radboud University, Radboudumc, HAN and ROC, businesses, local authorities and the province are represented on its board. Radboudumc and Byondis are currently exploring whether they can establish a joint chair.” Timmers points out that providing education is part of our social responsibility. “People often work in a company like ours driven by a sense of idealism. What their work can achieve for others – in this case, the patient – is what counts. It is no coincidence that our slogan is ‘Make hope real’.”
Need for cooperation
Byondis has everything in-house to take a project from discovery to innovation: it conducts research into potential new medicines, manufactures them, carries out pre-clinical and clinical trials, and also manages the entire registration process. Its short lines of communication and flat organisational structure set Byondis apart from the very large pharmaceutical companies. Timmers: “We are, however, the largest private Dutch biopharmaceutical company. To make a real impact and bring innovative pharmaceutical products to market, it is important to support smaller companies and encourage collaboration. We need each other to successfully tackle the societal challenges we face.”
This article appeared in a slightly different form in the magazine Arnhem Nijmegen Business.